Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -8.61% is 31% above its 5-year average of -12.40%, near the high end of its 5-year range (-31.41%–-1.26%).
12.77% above its 12-month average of -9.87%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -1.35%.
RETURN ON ASSETS (ROA)
-8.61%
RETURN ON ASSETS (ROA) AVG TTM
-9.87%
RETURN ON ASSETS (ROA) AVG 3Y
-17.96%
RETURN ON ASSETS (ROA) AVG 5Y
-12.40%
RETURN ON ASSETS (ROA) AVG 10Y
-2.86%
RETURN ON ASSETS (ROA) AVG 15Y
-0.18%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+12.77%
CURRENT VS 3Y AVG
+52.05%
CURRENT VS 5Y AVG
+30.55%
CURRENT VS 10Y AVG
-200.67%
CURRENT VS 15Y AVG
-4703.86%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-28.05%
median of 560 covered companies
CURRENT VS SECTOR MEDIAN
+69.30%
vs the sector median at left
Inogen, Inc.
Market Cap
$159.74M
Return on Assets (ROA)
-8.61%
TTM Avg
-9.87%
3Y Avg
-17.96%
5Y Avg
-12.40%
Market Cap
$160.80M
Return on Assets (ROA)
-50.30%
TTM Avg
-131.74%
3Y Avg
-92.52%
5Y Avg
-67.08%
Market Cap
$158.01M
Return on Assets (ROA)
-20.01%
TTM Avg
-38.20%
3Y Avg
-34.64%
5Y Avg
-39.69%
Market Cap
$156.62M
Return on Assets (ROA)
N/A
TTM Avg
-34.95%
3Y Avg
-49.76%
5Y Avg
-43.08%
Market Cap
$155.62M
Return on Assets (ROA)
-127.14%
TTM Avg
-129.15%
3Y Avg
-91.50%
5Y Avg
-82.73%
Market Cap
$154.76M
Return on Assets (ROA)
-25.59%
TTM Avg
-36.78%
3Y Avg
-35.70%
5Y Avg
-27.05%
Market Cap
$165.46M
Return on Assets (ROA)
-68.50%
TTM Avg
-29.78%
3Y Avg
-39.51%
5Y Avg
-30.76%
Market Cap
$153.56M
Return on Assets (ROA)
-35.50%
TTM Avg
-18.07%
3Y Avg
-62.20%
5Y Avg
-134.72%
Market Cap
$148.07M
Return on Assets (ROA)
-90.55%
TTM Avg
-70.80%
3Y Avg
-45.07%
5Y Avg
-40.08%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Inogen, Inc. (INGN) | $159.74M | -8.61% | -9.87% | -17.96% | -12.40% |
| ALX Oncology Holdings Inc. (ALXO)vs › | $160.80M | -50.30% | -131.74% | -92.52% | -67.08% |
| Anavex Life Sciences Corp. (AVXL)vs › | $158.01M | -20.01% | -38.20% | -34.64% | -39.69% |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $156.62M | N/A | -34.95% | -49.76% | -43.08% |
| Cardiol Therapeutics Inc. (CRDL)vs › | $155.62M | -127.14% | -129.15% | -91.50% | -82.73% |
| Codexis, Inc. (CDXS)vs › | $154.76M | -25.59% | -36.78% | -35.70% | -27.05% |
| Coherus Oncology, Inc. (CHRS)vs › | $165.46M | -68.50% | -29.78% | -39.51% | -30.76% |
| LifeMD, Inc. (LFMDP)vs › | $153.56M | -35.50% | -18.07% | -62.20% | -134.72% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $148.07M | -90.55% | -70.80% | -45.07% | -40.08% |
| Korsana Biosciences, Inc. (KRSA)vs › | $146.95M | -96.78% | -33.63% | -87.61% | -84.15% |
ROA
-8.6%
ROE
-14.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -7.62% |
| 2024-12-31 | -12.12% |
| 2023-12-31 | -31.41% |
| 2022-12-31 | -20.68% |
| 2021-12-31 | -1.29% |
| 2020-12-31 | -1.26% |
| 2019-12-31 | 4.68% |
| 2018-12-31 | 13.79% |
| 2017-12-31 | 7.64% |
| 2016-12-31 | 9.59% |
| 2015-12-31 | 7.18% |
| 2014-12-31 | 4.87% |
| 2013-12-31 | 30.87% |
| 2012-12-31 | 1.19% |
| 2011-12-31 | -8.30% |
